for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioDelivery Sciences International, Inc.

BDSI.OQ

Latest Trade

5.16USD

Change

0.01(+0.19%)

Volume

200,837

Today's Range

5.11

 - 

5.17

52 Week Range

2.84

 - 

5.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.15
Open
5.12
Volume
200,837
3M AVG Volume
13.50
Today's High
5.17
Today's Low
5.11
52 Week High
5.36
52 Week Low
2.84
Shares Out (MIL)
89.52
Market Cap (MIL)
461.04
Forward P/E
-23.88
Dividend (Yield %)
--

Next Event

Q3 2019 BioDelivery Sciences International Inc Earnings Release

Latest Developments

More

Biodelivery Sciences International Q2 GAAP Loss Per Share $0.13

Biodelivery Sciences International Files For Mixed Shelf Of Up to $125 Mln

Biopharma Credit Entered Into A Definitive Senior Secured Term Loan Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Industry

Biotechnology & Drugs

Contact Info

4131 Parklake Ave Ste 225

+1.919.5829050

https://www.bdsi.com/

Executive Leadership

Peter S. Greenleaf

Independent Chairman of the Board

Scott M. Plesha

President, Chief Commercial Officer

Herm Cukier

Chief Executive Officer, Director

Terry Coelho

Chief Financial Officer

Joseph Lockhart

Senior Vice President - Operations

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.250

2017

0.100

2018

-0.730

2019(E)

-0.216
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.65
Price To Book (MRQ)
6.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
88.36
LT Debt To Equity (MRQ)
88.36
Return on Investment (TTM)
-25.67
Return on Equity (TTM)
-19.90

Latest News

Latest News

BRIEF-BioDelivery Sciences Appoints Herm Cukier As CEO

* BIODELIVERY SCIENCES APPOINTS HERM CUKIER AS CHIEF EXECUTIVE OFFICER

BRIEF-Broadfin Says Delivered Letter To BioDelivery Sciences With Nominations For Board

* BROADFIN - ON APRIL 27, DELIVERED LETTER TO BIODELIVERY SCIENCES NOMINATING TODD C. DAVIS, PETER S. GREENLEAF, STEPHEN T. WILLS FOR ELECTION TO BOARD

BRIEF-Biodelivery Sciences Reports Q4 Loss Per Share $0.29

Biodelivery Sciences International Inc :

BRIEF-Biodelivery Sciences Announces Belbuca Patent Litigation Settlement Agreement With Teva

* BIODELIVERY SCIENCES ANNOUNCES BELBUCA PATENT LITIGATION SETTLEMENT AGREEMENT WITH TEVA

BRIEF-BioDelivery Sciences Announces Launch And Availability Of Belbuca In Canada

* BIODELIVERY SCIENCES ANNOUNCES LAUNCH AND AVAILABILITY OF BELBUCA® IN CANADA Source text for Eikon: Further company coverage:

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary

* BIODELIVERY SCIENCES - OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL

BRIEF-BioDelivery Sciences reports Q3 loss per share $0.21

* BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

BRIEF-BioDelivery Sciences CEO Mark Sirgo to retire

* BioDelivery Sciences president and chief executive officer Mark Sirgo to retire at year-end while continuing as vice chairman

BRIEF-BioDelivery Sciences reports Q2 loss per share $0.27

* BioDelivery Sciences reports second quarter 2017 financial results and provides corporate update

BRIEF-Biodelivery Sciences signs agreement with Purdue Pharma

* Biodelivery Sciences signs exclusive agreement with Purdue Pharma (Canada) for the licensing and distribution rights of Belbuca in Canada

BRIEF-Biodelivery Sciences announces Health Canada approval of Belbuca

* Biodelivery Sciences announces Health Canada approval of Belbuca®

BRIEF-BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca, Bunavail

* BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca® and Bunavail® through 2020

BRIEF-Biodelivery Sciences Q1 earnings per share $0.87

* Biodelivery Sciences International Inc - net revenue for Q1 ended March 31, 2017, was approximately $29.5 million.

BRIEF-Biodelivery Sciences International files for non-timely 10-Q - SEC Filing

* Biodelivery Sciences International Inc says requires up to five additional days to file form 10-Q for the fiscal quarter ended March 31, 2017

BRIEF-BioDelivery Sciences announces approval of BUNAVAIL

* Biodelivery sciences announces the approval of bunavail® for induction of buprenorphine treatment for opioid dependence

BRIEF-BioDelivery Sciences Q4 loss per share $0.29

* Biodelivery sciences provides corporate update and reports fourth quarter and full-year 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up